

References

I-169

1. Hensley ML, Patel SR, von Mehren M, et al. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *GynecoOncol.* 2017;146(3):531-537.
2. Morioka H, Takahashi S, Araki N, et al. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. *BMC Cancer.* 2016;16:479.
3. Patel S, von Mehren M, Reed D, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. 2019;125(15):2610-2620.
4. Stacchiotti S, Mir O, Le Cesne A, et. al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. *Oncologist*, 2018; 23(1):62-70.
5. Angarita FA, Cannel AJ, Abdul Razak AR, et. al. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study. *BMC Cancer.* 2016;16:1-11.
6. Trabectedin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated October 24, 2016.
7. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Trabectedin.
8. Micromedex DrugDex Compendium®. 2024. Trabectedin.
9. National Comprehensive Cancer Network (NCCN). Trabectedin. NCCN Drugs and Biologics Compendium®. 2024.
10. Yondelis (trabectedin) for injection, for intravenous use [package insert]. Janssen Product, LP. Horsham, PA. Revised 06/2020.